Leidos Holdings has clawed back ground this week, and the options market — which was flashing its loudest distress signal in months just days ago — has quietly stepped back from the ledge.
The shift in options positioning is the clearest change from last week's note. The put/call ratio has retreated to 0.96 from the 1.34–1.39 range that dominated mid-May, pulling the z-score down to 0.74 — back inside one standard deviation of the 20-day mean of 0.80. That's a meaningful de-escalation. Investors who were actively buying downside protection at elevated prices through May 18–19 have not renewed that hedging with the same intensity. The PCR is now running closer to neutral than to defensive, a notable reversal after a week when options positioning was the primary story.
Short interest tells a consistent story: there is no meaningful bear conviction here. SI runs at 2.6% of free float and has fallen roughly 13% over the past month — the absolute share count dropped from around 3.75 million in mid-April to 3.27 million now. The lending market is extraordinarily loose. Availability is at nearly 6,942% of short interest, meaning shares to borrow are essentially unconstrained. Cost to borrow spiked sharply on May 26 to 1.77% from 0.36% the prior day — a more than four-fold jump — but the absolute level remains low and the pool is deep. That one-day move in CTB is worth monitoring but does not yet signal any structural tightening in the borrow market.
The Street's posture is cautious but not bearish. The consensus holds at buy, with a mean price target of $186.27 — implying roughly 45% upside from the current $128.12. But the direction of travel on targets has been uniformly downward. Citigroup trimmed its target from $232 to $178 on May 7, maintaining Buy. RBC Capital and Stifel both cut targets in early May as well — from $215 to $180 and $205 to $193 respectively. The pattern is consistent: analysts are keeping their ratings but marking down their conviction on valuation after the stock's 12% one-month slide. Wells Fargo initiated at Equal-Weight with a $165 target in April, a notably cautious entry point for a new coverage initiation. The bull case centres on Entrust acquisition accretion and a second-half revenue rebound; the bear case is simple — government contract exposure leaves earnings vulnerable to budget timing and political disruption, and the Q1 print already demonstrated how severe that can be, with the stock falling 9.3% on the day and 13.7% over the following five sessions.
Insider activity adds a modest cautionary note. The 90-day net insider position shows roughly 21,350 net shares sold, worth approximately $3.5 million. CEO Tom Bell sold 2,530 shares at $148.81 on May 5 — the day of the earnings rout — and an independent director sold twice in the same week. None of these are large in the context of the company's market cap, and the significance scores are low, but the direction is consistently one-way: every recent trade on the insider register is a sale, with no purchases on record in the dataset.
Among peers, Booz Allen Hamilton is the standout this week, up 6.7% over the past five days. SAIC added 5.6% and KBR gained 4.0%. Leidos has risen 1.7% over the same period — recovering, but lagging the sector's bounce. Amentum and CACI were flat to slightly negative, so Leidos sits in the middle of the peer pack rather than leading it.
The next scheduled earnings date is August 4. With options hedging having unwound from its recent extreme and short interest continuing to drift lower, the immediate setup looks less charged than it did a week ago — but with targets still clustered well above the current price and the stock trading at a P/E of around 10x, the gap between where analysts stand and where the stock is sitting will be the central tension heading into the summer print.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
